Immunization News and Research

RSS

Experimental Chinese SARS-CoV-2 vaccine appears safe in early trials

A new study published on the preprint server medRxiv in October 2020 reports the findings of a phase I trial of an inactivated SARS-CoV-2 vaccine, demonstrating that it can elicit a potent immune response without significant adverse reactions.

7 Oct 2020

Researchers hope to develop an effective COVID-19 vaccine using bovine adenovirus

A researcher in Penn State's College of Agricultural Sciences is part of a team of scientists working to develop a unique COVID-19 vaccine that uses a bovine adenovirus as a safe and effective delivery vehicle.

7 Oct 2020

Study shows COVID-19 vulnerability increases exponentially with age

Aging-US recently published "From Causes of Aging to Death from COVID-19" by Blagosklonny et al. which reported that COVID-19 is not deadly early in life, but mortality increases exponentially with age - which is the strongest predictor of mortality.

7 Oct 2020

HPV vaccination mandates did not improve rates of HPV vaccine series completion, shows study

A postdoctoral researcher at the University of California, Riverside, has discovered human papillomavirus, or HPV, vaccination mandates fall short of ensuring both higher levels of uptake and equal uptake of the vaccine across socioeconomic and racial-ethnic groups.

6 Oct 2020

Production of six monoclonal antibodies against SARS-CoV-2 spike protein

Youjia Guo et al. in a recent bioRxiv preprint paper demonstrate the robust performance of mouse anti-SARS-CoV-2 spike monoclonal antibodies in immunoassays, including western blotting, ELISA, immunofluorescence, and immunoprecipitation and also neutralizing activity in vitro against SARS-CoV-2 infection.

5 Oct 2020

Less than 10% of US adults have SARS-CoV-2 antibodies

A new study by researchers at Stanford University and Ascend Clinical Laboratory and published in the journal The Lancet in September 2020 reports the prevalence of antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in a dialysis patient population in the US.

5 Oct 2020

Supporting Coronavirus Research with Liquid Chromatography

The RNA in viruses such as SARS-CoV-2 are an ideal research target. RNA purification with liquid chromatography is essential in the fight against SARS-CoV-2.

From KNAUER Wissenschaftliche Geräte GmbH 5 Oct 2020

Newly developed fusion protein could improve COVID-19 research

Researchers at the Paul Scherrer Institute in Switzerland have developed a high-quality recombinant virus protein that could be applied in the development of vaccines against the 2019 novel coronavirus (2019-nCoV) and in the detection of novel viruses or antibodies.

30 Sep 2020

Dartmouth TB vaccine moves one step closer to a full Phase 3 efficacy trial

Results from the Phase 2 trial of the DAR-901 tuberculosis (TB) vaccine were announced today by investigators at Dartmouth's Geisel School of Medicine and published in the journal Vaccine.

29 Sep 2020

J&J's COVID-19 vaccine shows potent immune response in phase 2 human trial

A multicenter phase 1/2a randomized, double-blinded, placebo-controlled clinical trial has been conducted recently to evaluate the safety, reactogenicity, and immunogenicity of a non-replicating adenovirus-based vaccine, namely Ad26.COV2.S against severe acute respiratory coronavirus 2 (SARS-CoV-2) infection.

28 Sep 2020

New trial tests combination antibody treatment for preventing COVID-19 illness

A combination antibody treatment for preventing COVID-19 illness in individuals who have had sustained exposure to someone with the virus is being studied by researchers at The University of Texas Health Science Center at Houston.

25 Sep 2020

Conflict, climate instability, and COVID-19 are affecting the health of women and children

Fragile gains made to advance women and children's health are threatened by conflict, the climate crisis and COVID-19, according to a new report from Every Woman Every Child.

25 Sep 2020

A possible inverse relationship between Dengue and COVID-19 in Brazil

Their study titled, “How super-spreader cities, highways, hospital bed availability, and dengue fever influenced the COVID-19 epidemic in Brazil,” was released pre-peer review on the preprint medRxiv* early this week.

24 Sep 2020

New initiative launched to combat the spread of disinformation on COVID-19

The Coronavirus disease (COVID-19) is the first pandemic in history in which technology and social media are being used on a massive scale to keep people safe, informed, productive and connected.

24 Sep 2020

New T-cell-based vaccine strategy provides broader protection against seasonal influenza

As Americans begin pulling up their sleeves for an annual flu vaccine, researchers at the University of Wisconsin-Madison have provided new insights into an alternative vaccine approach that provides broader protection against seasonal influenza.

23 Sep 2020

A subunit SARS-CoV-2 vaccine may offer broader protection against virus

A new study published in the preprint server bioRxiv in September 2020 reports on the structure of this protein, as revealed by cryo-electron microscopy (cryoEM).

23 Sep 2020

BCG vaccine may offer protection against COVID-19, shows study

While scientists race to develop and test a vaccine effective against SARS-CoV-2, the virus that causes COVID-19, recent studies have indicated that countries with widespread BCG vaccination appear to be weathering the pandemic better than their counterparts.

22 Sep 2020

Immunization is critical to protect current and future generations from preventable diseases

COVID-19 pandemic has shown the world that vaccines should be prioritised, writes Githinji Gitahi. Imagine a world in which everyone is at risk of contracting a contagious disease with no prevention or cure.

21 Sep 2020

COVAM assay may help select convalescent plasma units for treatment of acute COVID-19

A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.

21 Sep 2020

Oxford University and AstraZeneca resume COVID-19 vaccine trial

More than a hundred candidate vaccine trials against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19), are underway. About 35 are now undergoing clinical evaluation, and of these, nine are in the final phase of human trials, including the vaccine developed by Oxford University and the biopharmaceutical firm, AstraZeneca.

14 Sep 2020